Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q2 FY2024-25 Earnings Presentation
9 slides from Orchid Pharma's earnings presentation, Nov 11, 2024
Slide 1: Regulation 30 intimation letter to NSE and BSE
November 11, 2024 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Ref: (i) Regulation 30 of Securities and Exchange Board of India (
Slide 2: Orchid Pharma Limited Financials Q2 & FY 2024-25
Orchid Pharma Limited Financials Q2 & FY 2024-25 • All results in Standalone basis. • These are approx. nos. for exact nos. pls refer financials.
Slide 3: Financial Highlights QTR-2 6M-25
Financial Highlights QTR-2 6M-25 12% 22% 20% 44% 26% 76% 26% 76%
Slide 4: Financial Performance Summary
Financial Performance Summary 12M-31st (Rs/Crore) Q2-2025 Q2-2024 Change % 6M-2025 6M-2024 Change % Mar’24 Sales 222.7 198.8 +12% 467.1 381.7 +22% 819.4 Other Income 8.0 7.5 15.7 8.8 30.4 COGS 131.2 122.4 281.4 234.4 484.6 Employee Exp 20.7 17.2 42.0 33.4 69.6 Other Exp 41.3 35.5 80.8 68.0 154.6 EBI
Slide 5: Turnover (In Cr.)
Turnover (In Cr.) 250.0 222.7 198.8 200.0 165.2 150.0 121.9 104.7 100.0 50.0 - Q2-21 Q2-22 Q2-23 Q2-24 Q2-25
Slide 6: EBIDTA, PBT & PAT as % to Sales Q2-25
EBIDTA, PBT & PAT as % to Sales Q2-25 120.0% 100.0% 80.0% 60.0% 40.0% 23.7% 15.7% 16.8% 20.0% 7.6% 11.4% 0.0% 10.2% 11.5% -2.0% -20.0% -15.8% -17.0% -40.0% Q2-21 Q2-22 Q2-23 Q2-24 Q2-25 EBITDA PBT & PAT
Slide 7: P&L Analysis – Gross Margin % to Sales
P&L Analysis – Gross Margin % to Sales Gross Margin Quarterly Basis 70.0% 63.0% 60.0% 50.0% 41.1% 39.3% 39.7% 38.4% 40.0% 30.0% 20.0% 10.0% 0.0% Q2-21 Q2-22 Q2-23 Q2-24 Q2-25
Slide 8: P&L Analysis – Exp. % to Sales Q2-25
P&L Analysis – Exp. % to Sales Q2-25 30.0% 24.5% 25.0% 22.0% 20.0% 17.8% 17.9% 18.5% 16.0% 15.0% 13.0% 10.7% 8.7% 9.3% 10.0% 5.0% 0.0% Q2-21 Q2-22 Q2-23 Q2-24 Q2-25 Emp Benefit Other Exp
Slide 9: Thank You
Thank You